- Home
- SLDP vs GOSS Comparison
SLDP vs GOSS Comparison
Compare SLDP & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- GOSS
- Stock Information
- Founded
- SLDP 2011
- GOSS 2015
- Country
- SLDP United States
- GOSS United States
- Employees
- SLDP N/A
- GOSS N/A
- Industry
- SLDP Electrical Products
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- GOSS Health Care
- Exchange
- SLDP Nasdaq
- GOSS Nasdaq
- Market Cap
- SLDP 209.3M
- GOSS 188.6M
- IPO Year
- SLDP N/A
- GOSS 2019
- Fundamental
- Price
- SLDP $1.10
- GOSS $0.84
- Analyst Decision
- SLDP Buy
- GOSS Strong Buy
- Analyst Count
- SLDP 3
- GOSS 4
- Target Price
- SLDP $2.67
- GOSS $7.50
- AVG Volume (30 Days)
- SLDP 2.1M
- GOSS 1.5M
- Earning Date
- SLDP 05-06-2025
- GOSS 05-06-2025
- Dividend Yield
- SLDP N/A
- GOSS N/A
- EPS Growth
- SLDP N/A
- GOSS N/A
- EPS
- SLDP N/A
- GOSS N/A
- Revenue
- SLDP $20,139,000.00
- GOSS $114,701,000.00
- Revenue This Year
- SLDP $40.13
- GOSS N/A
- Revenue Next Year
- SLDP $54.82
- GOSS $172.31
- P/E Ratio
- SLDP N/A
- GOSS N/A
- Revenue Growth
- SLDP 15.68
- GOSS N/A
- 52 Week Low
- SLDP $0.68
- GOSS $0.50
- 52 Week High
- SLDP $2.70
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- SLDP 50.97
- GOSS 37.58
- Support Level
- SLDP $1.04
- GOSS $0.80
- Resistance Level
- SLDP $1.15
- GOSS $0.88
- Average True Range (ATR)
- SLDP 0.08
- GOSS 0.10
- MACD
- SLDP 0.02
- GOSS -0.01
- Stochastic Oscillator
- SLDP 89.36
- GOSS 20.24
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.